home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

2.910 -0.050 (-1.69%)

Official Closing Price Updated: 6:30 PM EDT, Apr 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Piclidenoson Takes On Otezla, a $13 Billion Psoriasis Drug ↗

December 14, 2021

Photo by Hal Gatewood on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...

Via Benzinga

Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022 ↗

December 07, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week...

Via Benzinga

Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022

December 07, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Cannabis-Focused Biotech Company Can-Fite Reports Q3 Financial Results & Clinical Updates ↗

November 26, 2021

Cannabis-focused biotech company Can-Fite BioPharma Ltd. (AMEX:C...

Via Benzinga

Earnings Scheduled For November 26, 2021 ↗

November 26, 2021

Companies Reporting Before The Bell Pinduoduo Inc. (NASDAQ:PDD) is expected to report quarterly earnings at $0.02 per share on revenue of $4.16 billion. BlueCity Holdings Limited...

Via Benzinga

Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021

November 24, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite's Kickstarts Piclidenoson Study For Canine Osteoarthritis ↗

November 23, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) has commenced a safety and efficacy study of Piclidenoson to treat osteoarthritis in dogs. Safety results are expected in...

Via Benzinga

Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis

November 23, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference

November 12, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference

November 01, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico

October 28, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit

October 26, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal ↗

October 21, 2021

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule...

Via Benzinga

Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal

October 21, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Hope on the Horizon for Liver Cancer Patients as This Company's Namodenoson Drug Starts Pivotal Phase III Global Trial ↗

October 08, 2021

Photo by National Cancer Institute on Unsplash Liver cancer is a growing global health concern. Apart from the financial burden it places on patients and economies, the American...

Via Benzinga

Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021

October 05, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021

September 22, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences

September 17, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

September 09, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study

September 02, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

The Week In Cannabis: $1.25B+ In Financings And M&A, Tilray, KushCo, New York And More ↗

August 27, 2021

Below is a recap of the main news related to the cannabis industry and markets for the week of August 27, 2021.

Via Benzinga

Topics Cannabis

Can-Fite Reports Drop In H1 2021 Revenue, Net Loss Down By 38% YoY ↗

August 26, 2021

Biotechnology company Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CFBI) announced its financial results Thursday for the quarter ended June 30, 2021. The Israel-based company...

Via Benzinga

Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update

August 26, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Announces $10.0 Million Registered Direct Offering

August 12, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board

August 05, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study

July 08, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗

July 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:...

Via Benzinga

Topics Product Recall

Can-Fite Stock Gains On Piclidenoson Development Pact For Pets ↗

June 28, 2021

Can-Fite BioPharma Ltd (NYSE: CANF) has signed a development and commercialization agreement with France-based veterinary biotech company, Vetbiolix, to...

Via Benzinga

Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets

June 28, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment

June 16, 2021

From Can-Fite BioPharma Ltd.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com